Skip to Content Facebook Feature Image

Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored

Asia Pacific

Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored
Asia Pacific

Asia Pacific

Broermann Medical Innovation Award 2026: Three Pioneers of Modern Obesity and Diabetes Therapies Honored

2026-11-17 23:47 Last Updated At:23:56

  • Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp honored for groundbreaking research on metabolic diseases and obesity therapies.
  • Minister-President Boris Rhein presents the medical award, endowed with a total of one million euros, at the Hessian State Chancellery.
  • Titia große Broermann: " this year's laureates powerfully demonstrate how scientific curiosity sparks medical progress that can transform millions of lives"

WIESBADEN, GERMANY – Newsaktuell – 17 November 2026 – Prof. Svetlana Mojsov (The Rockefeller University), Prof. Dr. Richard DiMarchi (Indiana University), and Prof. Dr. Dr. h.c. Matthias H. Tschöp (Ludwig-Maximilians-Universität München) have been awarded the Broermann Medical Innovation Award 2026. Hessian Minister-President Boris Rhein presented the award during a ceremony at the Hessian State Chancellery.

Endowed with a total of one million euros, the Broermann Medical Innovation Award ranks among the world´s highest-endowed medical honors. This year, it honors three scientists whose fundamental work contributed decisively to enabling modern GLP-1-based therapies against obesity and diabetes. The award was endowed by Dr. Bernard große Broermann, founder of the Asklepios Kliniken Group.

In the presence of representatives from science, politics, and society, Minister-President Boris Rhein praised the international significance of the honored research achievements:

Boris Rhein, Minister-President of Hesse: "Through their research, Prof. Dr. Richard D. DiMarchi, Prof. Dr. Svetlana Mojsov, and Prof. Dr. med. Dr. h.c. Matthias Tschöp have opened a new chapter in metabolic therapy. Their work laid the scientific foundation for what is colloquially known as the "weight-loss injection." From fundamental insights into human metabolism, a new generation of therapies has emerged, paving the way for effective treatments for diabetes and obesity, while also helping to manage or reduce associated secondary conditions."

Prof. Dr. Werner Seeger, Chairman of the Jury for the Broermann Award, emphasized: "The work of this year's laureates powerfully proves how scientific pioneering transforms into medical reality. Their discoveries surrounding GLP-1 and polyagonists have fundamentally redefined obesity and diabetes care, offering real hope to millions worldwide."

Prof. Svetlana Mojsov stated: "I am humbled and honored to receive the Broermann Award for my work on GLP-1 that began over 40 years ago with a hypothesis and has gone to benefit the health and lives of millions of people worldwide."

Prof. Dr. Richard DiMarchi noted: " In the last decade, based upon a half century of research we have progressed with incretin-based medicines to transform the management of excess body weight analogous to historical treatment of excess glucose, cholesterol, and blood pressure. It is providing a transformative advance in public health and patient well-being."

Prof. Dr. Dr. h.c. Matthias H. Tschöp added: "It is a great honor to receive this recognition together with Svetlana Mojsov and Richard DiMarchi. We are delighted that our decades of work on the scientific foundation and invention of therapeutic principles that ignited the modern obesity-drug revolution is receiving international recognition. It is especially rewarding to see how these discoveries are transforming the therapeutic landscape of diabetes, cardiovascular disease, fatty liver disease, and many other obesity-related conditions worldwide."

Titia Olivia große Broermann, Shareholder of the Asklepios Kliniken Group, added: "The Broermann Medical Innovation Award stands for the conviction that medical progress begins where scientific courage meets the determination to sustainably improve patients' lives. This year's awardees impressively demonstrate how scientific curiosity and decades of research can give rise to therapies that transform the lives of millions of people. With this award, we aim to make their outstanding achievements visible while encouraging researchers worldwide to forge new paths. On behalf of my family and the Asklepios Kliniken Group, I congratulate Prof. Mojsov, Prof. DiMarchi, and Prof. Tschöp from the bottom of my heart."

Foundations for a New Generation of Therapies

Prof. Svetlana Mojsov, Prof. Dr. Richard DiMarchi, and Prof. Dr. Dr. h.c. Matthias H. Tschöp were honord for their fundamental contributions to metabolic science. Their work on elucidating bioactive GLP-1, signal transmission between the gut and brain, and the development of multi-hormone co-agonists (polyagonists) laid the foundation for modern drugs for weight regulation and blood sugar control.

About the Award Winners

Prof. Svetlana Mojsov (born in Skopje, North Macedonia) earned her PhD in biochemistry at The Rockefeller University under Nobel laureate Bruce Merrifield, focusing on solid-phase peptide synthesis. During her research at Massachusetts General Hospital and Harvard Medical School in the 1980s, she identified and chemically synthesized the active 31-amino-acid form of Glucagon-Like Peptide-1 (GLP-1) and demonstrated its physiological role in stimulating insulin secretion. Her groundbreaking discoveries proved vital for the later development of GLP-1 receptor agonists. She currently serves as a Research Professor at The Rockefeller University in New York.

Prof. Dr. Richard DiMarchi (born in New York, USA) earned his PhD in biochemistry at Indiana University. Following academic research at The Rockefeller University, he led major research and development divisions at Eli Lilly and Company for over two decades, where he played a pioneering role in shaping the development of human insulin and analogues (Humalog®) and rHGH (Humatrope®) As a world-renowned peptide chemist and innovator, he holds over 100 patents and has co-founded eight successful biotech companies. He is currently Distinguished Professor of Chemistry and Gill Chair in Biomolecular Sciences at Indiana University.

Prof. Dr. Dr. h.c. Matthias H. Tschöp (born in Munich, Germany) completed his medical studies at Ludwig-Maximilians-Universität (LMU) München. Following clinical work in endocrinology and research at Eli Lilly, he established research laboratories at the University of Cincinnati and Helmholtz Munich. Tschöp discovered the key role of ghrelin as the hunger hormon and, in close collaboration with Richard DiMarchi, developed the concept of multi-hormone co-agonists (dual and triple gut hormone receptor agonists such as GLP-1/GIP and GLP-1/GIP/glucagon molecules). He currently serves as President of LMU Munich.

About the Broermann Medical Innovation Award

The Broermann Medical Innovation Award was established in 2024 by Dr. Bernard große Broermann, namesake and founder of Asklepios Kliniken. Throughout his lifetime, Dr. große Broermann was distinguished by his vision of creating an innovative healthcare company that delivers genuine benefits to people. Under his leadership, Asklepios set standards in medical innovation, targeted investments in state-of-the-art medical technology and digital solutions, and thereby advanced patient care—values that also

form the foundation of the Broermann Medical Innovation Award. Through this award, his vision lives on and underscores a commitment that endures beyond his lifetime through his foundation.

2027 Nomination Phase

The nomination phase for the Broermann Medical Innovation Award 2027 has begun. Scientists from around the world can be nominated until March 1, 2027. Further information on the award, nomination criteria, and the selection process is available on the Award-Website

High-resolution photos of the award ceremony will be available for download shortly after the event at the following website: https://www.broermann-award.org/press/

Broermann Medical Innovation Award
www.broermann-award.com
www.facebook.com/people/Broermann-Medical-Innovation-Award/61567211302915/
www.linkedin.com/company/broermann-medical-innovation-award/
www.instagram.com/broermannaward

Asklepios Kliniken
Visit Asklepios online and on social media:
www.asklepios.com
www.asklepios.com/gesundheitsmagazin
http://www.youtube.com/asklepioskliniken
de.linkedin.com/company/asklepios
www.instagram.com/asklepioskliniken/
www.facebook.com/asklepioskliniken
www.tiktok.com/@asklepioskliniken

The issuer is solely responsible for the content of this announcement.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

After more than a decade developing cloud-based browser technology, CloudMosa is reintroducing Puffin Secure Browser with a security-first architecture at its core to help address AI-driven cyberattacks.

CUPERTINO, US – Media OutReach Newswire – 18 November 2026 – CloudMosa today announced the latest release of its Puffin Secure Browser, bringing its cloud-based technology back into focus with security at the forefront. Developed more than 15 years ago, Puffin's split-browser architecture moves vulnerable web processing to the cloud, while keeping the user's device focused on displaying the visual result. This approach eliminates endpoint exposure to malicious web content as online threats continue to evolve.

Puffin Secure Browser is back with a security-first focus built on its proven cloud architecture

Puffin Secure Browser is back with a security-first focus built on its proven cloud architecture

Most clicks on links, attachments, and updates are made for routine reasons rather than bad intent, yet web-based threats continue to grow more sophisticated. As organizations and individuals rely on browsers for more of their daily activities, the browser itself has become an important consideration for cybersecurity. Research shows that more than 85% of enterprise workloads are projected to be accessed through the browser by 2027. Malicious websites, web-based malware, and zero-day exploits can target vulnerabilities in browser components. The emergence of AI-assisted threats adds to the challenge, with attacks by AI-enabled adversaries up 89% year on year, reinforcing the need to consider how and where web content is processed.

A different approach to everyday browsing
Puffin's split-browser architecture is inherently built to separate heavy, high-risk web execution from local endpoints. Through its Network Vector Rendering technology, approximately 95% of HTML rendering takes place in the cloud, while the device handles the remaining display rasterization. This approach delivers a responsive browsing experience while keeping the on-device component lightweight and secure.

Now powered by the same split-browser architecture, Puffin returns to its security-first foundation. Rather than executing complex web rendering entirely on the local device, Puffin isolates and executes potentially malicious JavaScript within a cloud sandbox, helping achieve zero contact between the endpoint and unknown threats. The browsing experience is then delivered through a thin client-side layer, combining this added layer of protection with the lightweight performance Puffin is known for.

"For years, Puffin has been recognized for its speed, but true browser security requires rethinking where web processing actually happens," said Shioupyn Shen, CEO of CloudMosa. "With Puffin Secure Browser, security is the priority. When it comes to modern work, click happens. But no one's click rate will ever be zero, so security shouldn't depend on perfect behavior. We want people to click, explore and follow their curiosity across the web with more confidence, without constantly wondering what might be hiding behind the next link. That's why Puffin processes web content in the cloud rather than on the user's device, so people can explore with greater peace of mind."

Cloud-based protection for a changing web
Puffin was among the most downloaded browsers of the 2010s, trusted by hundreds of millions across its iOS and Android versions. It now unveils the Puffin Secure Browser, built with a security-first mindset naturally in its DNA. With more than 200 million downloads over its history, Puffin brings an established browsing architecture to an evolving security landscape. CloudMosa also reports no security breaches across that period.

Puffin Secure Browser is designed for browsing scenarios that involve everyday risks, such as clicking links in emails, visiting unfamiliar websites, or accessing third-party web content. By isolating vulnerable web processing from the endpoint, it can complement existing security measures and help individuals and organizations manage browser-related risks across employee, contractor, and other browsing environments.

Most people browse the web simply to get things done, discover information and explore new ideas. Security should support that everyday freedom, not make people more hesitant to click. With Puffin Secure Browser, CloudMosa aims to make safer browsing more accessible, giving users greater confidence to navigate the web while helping reduce exposure to potentially malicious content.

The latest Puffin Secure Browser is available to download for free on Windows and macOS. Users can visit puffin.com/secure-browser to get started, or learn more about CloudMosa at cloudmosa.com.
Hashtag: #CloudMosa #Cybersecurity


The issuer is solely responsible for the content of this announcement.

CloudMosa

CloudMosa is a pioneer in cloud computing and remote browser solutions for both consumers and enterprises. For over a decade, CloudMosa has developed technology that moves web processing into the cloud, helping devices stay light, fast, and secure. This began with the Puffin browser, downloaded more than 200 million times, and now includes Puffin Secure Browser for security-focused browsing and Cloud Phone, which brings internet and app experiences to affordable feature phones. To learn more, visit for Puffin, or for Cloud Phone.

** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **

Recommended Articles